Allergy & Immunology
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
27 Jul, 2021 | 03:48h | UTCImmunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination – Nature Medicine
Commentary: A ‘mix and match’ approach to SARS-CoV-2 vaccination – Nature Medicine
Related:
WHO warns against mixing and matching COVID vaccines.
Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Commentary on Twitter
A study in @NatureMedicine shows that using a mRNA COVID-19 vaccine as a booster after a dose of the Oxford/AstraZeneca vaccine generated a better immune response. https://t.co/2jOprd0dO6 pic.twitter.com/9tK55KpgCM
— Nature Portfolio (@NaturePortfolio) July 26, 2021
[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.
27 Jul, 2021 | 03:50h | UTCNews release: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity – Newcastle University
Original Study (preprint): Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine
Commentaries:
Related:
Debate: Should we delay second vaccine doses to give one dose of the Covid-19 vaccine to more people? (several texts on the subject)
Safety evaluation of the second dose of mRNA COVID-19 vaccines in patients with immediate reactions to the first dose.
27 Jul, 2021 | 03:42h | UTCCommentaries:
No anaphylaxis after second dose of mRNA COVID vaccine, study finds – CIDRAP
Commentary on Twitter
For people who had an immediate allergic reaction to a 1st dose mRNA vaccine, a multicenter study shows the 2nd dose can be given safelyhttps://t.co/Y3dxz37G0B @JAMAInternalMed @KimberlyBlumen1 and colleagues pic.twitter.com/rpCncauT4S
— Eric Topol (@EricTopol) July 26, 2021
CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness.
27 Jul, 2021 | 03:38h | UTCRelated:
RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.
WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.
Brazilian town experiment shows mass vaccination can wipe out COVID-19.
Study: Lateral flow antigen testing can rapidly and accurately detect early COVID-19 among patients presenting with flu-like illness and can be a plausible alternative to RT-PCR.
26 Jul, 2021 | 02:56h | UTCNews release: Lateral flow tests are 95% effective at detecting Covid-19 when used at the onset of symptoms – University of Oxford
Related:
Rapid point-of-care tests for diagnosing COVID-19 infection: the latest Cochrane evidence
Commentary on Twitter (thread – click for more)
Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)
Thread on today's @EDGEclinical paper, with some recommendations at the end for how we can improve UK testing. ?
— The Sharing Scientist (@ScienceShared) July 14, 2021
Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.
26 Jul, 2021 | 02:54h | UTCCommentary: Case Mounts for COVID Vaccine Boosters in Kidney Transplant Recipients – MedPage Today (free registration required)
Related:
[Preprint] 3rd AstraZeneca shot gives strong immunity.
Commentary on Twitter
JUST PUBLISHED @JAMANetwork
✔️N=159 kidney #transplant recipients
✔️3rd dose of #mRNA #Moderna #vaccine induced a #serologic response in 49% of kidney transplant recipients who did not respond after 2 doseshttps://t.co/NCDyraI98x#RealTimeCOVID19 @IDSAInfo @HIV_TID @AST_info— COVID-19 Real-Time Learning Network (RTLN) (@RealTimeCOVID19) July 24, 2021
Case report: Kawasaki-like multisystem inflammatory syndrome associated with SARS-CoV-2 infection in an adult.
26 Jul, 2021 | 02:52h | UTCRelated:
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection
Case Reports: 2 Adults with Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19
Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.
23 Jul, 2021 | 10:51h | UTCTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.
22 Jul, 2021 | 11:16h | UTCCommentaries: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes AND Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider
Related: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. AND Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. AND Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
Commentary on Twitter
Public Health England's test-negative case-control study for Delta variant now in NEJM: over 14,000 people with Alpha, over 4,000 with Delta https://t.co/3l1QhKeXBT
Vax effectiveness against testing positive for Delta after 2 doses:
– BNT-Pfizer 88.0% (85-90)
– AZ 67.0% (61-72) pic.twitter.com/9UFy6CLSWw— Hilda Bastian, PhD (@hildabast) July 21, 2021
COVID-19 antibodies persist at least nine months after infection – “98.8 percent of people infected in February/March showed detectable levels of antibodies in November”.
22 Jul, 2021 | 11:14h | UTCNews release: COVID-19 antibodies persist at least nine months after infection – Imperial College London
Original study: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications
Guideline on the management of IgE-mediated food allergies.
22 Jul, 2021 | 10:34h | UTCUpdate of the S2k guideline on the management of IgE-mediated food allergies – Allergologie Select
Experts recommend Covid jabs for some under-18s in UK – “advice is that 16 to 18-year-olds can be offered a Pfizer jab if they are in a priority group or live with someone who has a weakened immune system”.
20 Jul, 2021 | 10:15h | UTCCommentaries: Experts recommend Covid jabs for some under-18s in UK – BBC
Position Paper: Recommendations for the use of topical inhalant budesonide in COVID-19.
18 Jul, 2021 | 23:53h | UTCRecommendations for use of topical inhalant budesonide in COVID-19 – HNO
Related: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 AND Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19
Studies elucidate poorly understood long COVID.
18 Jul, 2021 | 23:42h | UTCStudies elucidate poorly understood long COVID – CIDRAP
Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.
16 Jul, 2021 | 11:06h | UTCLong-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – JAMA
Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.
16 Jul, 2021 | 11:02h | UTCHeterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine
Related: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Commentary on Twitter
Health care workers who had received a dose of ChAdOx1 nCoV-19 were offered either ChAdOx1 nCoV-19 or mRNA-1273 9 to 12 weeks later. Levels of S-specific and RBD-specific IgG increased by a factor of 5 after ChAdOx1 nCoV-19 and by a factor of 115 to 125 after mRNA-1273.
— NEJM (@NEJM) July 14, 2021
Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.
16 Jul, 2021 | 11:00h | UTCHeterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine
Related: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Commentary on Twitter
Mix and match vaccines?
2 doses AZ vs AZ and then Pfizer:
"BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants" https://t.co/53J2erWVMy pic.twitter.com/aEmqMlhEar— Eric Topol (@EricTopol) July 14, 2021
RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).
15 Jul, 2021 | 09:26h | UTCBamlanivimab plus Etesevimab in Mild or Moderate Covid-19 – New England Journal of Medicine
Long COVID and kids: scientists race to find answers – “Children get long COVID too, but researchers are still working to determine how frequently and how severely”.
15 Jul, 2021 | 09:23h | UTCLong COVID and kids: scientists race to find answers – Nature
Millions of children worldwide missed routine vaccinations during the pandemic, study suggests.
15 Jul, 2021 | 09:24h | UTCMillions of children worldwide missed routine vaccinations during the pandemic, study suggests – CNN
Invited Commentary: Disruptions to childhood immunisation due to the COVID-19 pandemic – The Lancet
Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.
14 Jul, 2021 | 11:20h | UTCBetween BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women – JAMA
Commentary: Pfizer COVID vaccine shows 78% efficacy in pregnancy – CIDRAP
New Zealand children falling ill in high numbers due to Covid ‘immunity debt’.
14 Jul, 2021 | 11:16h | UTCNew Zealand children falling ill in high numbers due to Covid ‘immunity debt’ – The Guardian
Related: New Zealand, where Covid-19 is dormant, fights another respiratory virus – The New York Times
Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.
13 Jul, 2021 | 09:57h | UTCCommentaries: Long COVID symptoms in a third of people with COVID-19 – American College of Physicians AND Covid-19: 1-in-3 Patients Reported Long-Hauler Symptoms – Physician’s Weekly
Commentary on Twitter
A new prospective cohort study of >400 people with mild to moderate (outpatient) covid at 7-9 months: nearly 1 of 3 had persistent symptoms #LongCovid @AnnalsofIM
https://t.co/ix1Hhsm0iZ
by @mayssamnehme and colleagues pic.twitter.com/Uc4UEclDvA— Eric Topol (@EricTopol) July 5, 2021
WHO warns against mixing and matching COVID vaccines.
13 Jul, 2021 | 09:53h | UTCWHO warns against mixing and matching COVID vaccines – Reuters
Commentary: WHO cautions data still limited on mixing COVID-19 vaccines, but Canadian officials say it’s OK – CTV News
Related: Germany issues world’s strongest recommendation for mixing Covid-19 vaccines. AND [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Perspective | Can I get AstraZeneca now and Pfizer later? Why mixing and matching COVID vaccines could help solve many rollout problems. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects. AND Should you mix and match COVID-19 vaccines? Scientists are seeking answers
Commentary on Twitter
The World Health Organization's chief scientist on Monday advised against people mixing and matching COVID-19 vaccines from different manufacturers, calling it a "dangerous trend" since there was little data available about the health impact. https://t.co/Oog6fWDSMz
— Reuters Health (@Reuters_Health) July 13, 2021
[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.
13 Jul, 2021 | 09:55h | UTCCommentary: Study explores the prevalence of long COVID in England – News Medical